Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma.

Although the scores continued to improve, they did not reach statistical significance, possibly indicating stabilization of the intervention’s impact on daily functioning after the first few months.

also in 111,027 other papers